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Objective. To review our experience with intratympanic steroids (ITSs) for the treatment of idiopathic sudden sensorineural
hearing loss (ISSNHL), emphasizing the ideal time to perform follow-up audiograms. Methods. Retrospective case review of
patients diagnosed with ISSNHL treated with intratympanic methylprednisolone. Injections were repeated weekly with a total of
3 injections. Improvement was deﬁned as an improved pure-tone average ≥20dB or speech-discrimination score ≥20%. Results.
Forty patients met the inclusion criteria with a recovery rate of 45% (18/40). A signiﬁcantly increased response rate was found
in patients having an audiogram >5 weeks after the ﬁrst dose of ITS (9/13) over those tested ≤5 weeks after the ﬁrst dose of ITS
(9/27) (P = 0.03). Conclusions. Recovery from ISSNHL after ITS injections occurs more frequently >5 weeks after initiating ITS.
This may be due to the natural history of sudden hearing loss or the prolonged eﬀect of steroid in the inner ear.
1.Introduction
Sudden hearing loss is a devastating disease for patients and
represents a true otologic emergency. The etiologies of sud-
den hearing loss are many, but only about 10–15% of cases
have an identiﬁable cause [1]. Oral steroids have been eﬀec-
tive in many patients and currently represent the standard
treatment for idiopathic sudden sensorineural hearing loss
(ISSNHL) [2–4].
Intratympanic steroids (ITSs) may treat ISSNHL more
eﬀectively than oral steroids [5–12]. Data to support this
hypothesisarelimitedalmostexclusivelytocaseseries,which
diﬀer in the type of steroid used, the steroid dose, the dose
frequency, the method of injection, the existence of previous
treatment with oral steroids, and the outcome measure-
ments. In addition, these studies do not speciﬁcally address
the timing of the posttreatment audiogram in determining
treatment success. We reviewed our experience with ITS,
which included an analysis of the timing of post-treatment
audiograms. In doing so we sought to determine if there
is a diﬀerent recovery rate depending on when audiograms
are performed after completing ITS treatment. Most cases of
sudden hearing loss are idiopathic not because they do not
have a cause but because we are unable to identify it. We
presumed that any group of idiopathic hearing loss patients
is a heterogeneous one with variable response to steroids and
a variable time course to recovery including both early and
late responders.
2.MaterialsandMethods
2.1. Inclusion Criteria. After obtaining institutional board
approval,weperformedaretrospectivechartreviewofallpa-
tients undergoing ITS injection at our tertiary referral center
from October 2001 to July 2008. To be included in the
study, patients had to have a sensorineural hearing loss
of at least 30dB in 3 contiguous frequencies occurring in
less than 72 hours. Additional inclusion and exclusion2 International Journal of Otolaryngology
Table 1: Inclusion and exclusion Criteria.
30dB loss in 3 consecutive frequencies in <72 hours
Pre- and post-treatment audiogram including PTA and SDS
Normal or near normal hearing in the contralateral ear normal
otoscopic exam
Normal MRI with contrast of the brain and internal auditory
canals
Negative serologic studies for infectious and inﬂammatory disease
No history of chronic otitis media
No history of trauma (head, acoustic, or barometric)
No history of Meniere’s disease, hydrops, or ﬂuctuating hearing
loss
No history of meningitis
No history of prior ear surgery
No history of radiation
No exposure to ototoxic mediations
dB: decibel; PTA: pure tone average; SDS: speech discrimination score.
criteria are listed in Table 1. In all patients serologic studies
included an erythrocyte sedimentation rate, Lyme titer, anti-
nuclear antibody titer, rheumatoid factor, and a ﬂuorescent
treponemal antibody absorption (FTA-ABS) study.
2.2. Audiometric Measurements. Patients were evaluated for
pure-tone thresholds and speech intelligibility both before
and after steroid injection. The pure-tone average (PTA)
was calculated as an average of thresholds measured at 0.5,
1.0, and 2.0KHz. Speech-discrimination scores (SDSs) were
calculated as the percent of phonetically balanced, monosyl-
labic words pronounced correctly.
2.3. Method of Intratympanic Injection. First, phenol was
applied topically to anesthetize the posterior inferior quad-
rant of the tympanic membrane (the area overlying the
round window niche). A single myringotomy was then per-
formed with a disposable knife. Approximately 0.3 to 0.5mL
of 40mg/mL methylprednisolone mixed 9:1 with 2% lido-
caine was then delivered through the myringotomy via a 25
gauge spinal needle. The patients were then instructed to
maintain their head turned 45◦ away from the injected ear
in a reclined position for 30 minutes and were encouraged
not to swallow if possible. Injections were repeated at ap-
proximately one-week intervals for a total of 3 injections (3
injections over approximately 15 days).
2.4. Statistical Analysis. Statistical analysis was performed
using Microsoft Excel version 2002 (Redmond, WA) and
SAS version 9.2 (SAS Institute Inc, Cary, North Carolina).
Improvement was deﬁned as an improved pure-tone average
≥20dB or speech-discrimination score ≥20%. The variables
evaluated included time to post-treatment audiogram, age,
gender, sidedness of hearing loss, days from onset to ITS
treatment (>14 days), prior treatment with oral steroids,
presence of vertigo, and presence of tinnitus.
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The primary covariate of interest was the time to post-
treatmentaudiogramwhichwasdichotomizedat5weeks(35
days) after the ﬁrst dose of ITS. Pre-ITS PTA and SDS were
compared using paired t-tests. Since expected cell counts
were greater than ﬁve for all covariates, chi-square tests were
usedtodeterminetheassociationbetweencategoricalpatient
characteristics and improvement and t-tests were used for
continuous characteristics. Logistic regression was used to
estimate adjusted odds ratios and 95% conﬁdence intervals
for variables which were found to be signiﬁcant. Variable se-
lection for the model was based on the signiﬁcance (at 0.05
level) of univariate associations with improvement.
3. Results
3.1. Patient Characteristics. During the study period, 172
series of injections were performed in 151 patients with 60
patients diagnosed with ISSNHL. Of those 60, 13 were
excluded due to insuﬃcient data, and 7 were excluded be-
cause they did not have at least a 30dB hearing loss in 3
contiguous frequencies; therefore, a total of 40 patients were
included in the review.
The demographic information for our patient popula-
tionisdisplayedinTable 2. The average number of days from
theonsetofhearinglosstotheinitiationofITSwas22.7,with
a nearly equal distribution of patients starting treatment less
than 2 weeks (15), between 2 to 4 weeks (12), and greater
than 4 weeks (13) after the onset of hearing loss.
3.2. Rate and Degree of Recovery. The overall response rate
was 45% (18/40). PTA decreased an average of 17dB from
pre- to post-treatment (95% CI: −24, −11; P<0.001) and
SDS increased an average of 12% (95% CI: 2, 21; P = 0.02;
Table 3). Patients with serviceable hearing (deﬁned as a SDSInternational Journal of Otolaryngology 3
Table 3: Average pre- and post-treatment PTA and SDS.
Pre Post Diﬀ†
Mean SD Mean SD Mean SD P-value∗
PTA, dB 73 24 56 27 −17 21 <0.001
S D S , % 3 73 44 93 81 23 0 0 . 0 2
†Diﬀerence is post-pre.
∗P-values were calculated with a paired t-test.
PTA: pure tone average; SDS: speech discrimination score; dB: decibel.
≥50%andaPTA ≤50dB)increasedfrom7/40(17.5%)prior
to ITS to 15/40 (37.5%) after ITS.
3.3. Patient Characteristics Associated with Improvement.
Overall patient characteristics and improvement status are
shown in Table 4. The average number of days that an au-
diogram was performed was 33.2 days after the ﬁrst steroid
injection.Patientswhohadaudiometrictestingmorethan35
days (5 weeks) after the ﬁrst dose of ITS were more likely to
demonstrate hearing improvement than those who received
testing earlier (69% versus 33%; P = 0.03). The number of
days from hearing loss to starting ITS was not signiﬁcantly
diﬀerent between patients who had an audiogram at more
than 5 weeks or less than 5 weeks after the ﬁrst dose of ITS
(P = 0.32). Regression analysis was performed to determine
if either the days from hearing loss to the audiogram or the
days from starting ITS to the audiogram were signiﬁcant
(Figure 1). Neither the days from hearing loss to audiogram
(r2 = 0.087, d.f. =39, P = 0.06) nor the days from ITS to
audiogram(r2 = 0.0005,d.f.=39,P = 0.89)weresigniﬁcant,
although the former demonstrated a trend toward a lesser
likelihood of improvement with a longer duration of hearing
loss to audiogram. Patients who received ITS ≤21 days after
sudden hearing loss were more likely to improve than those
who had a treatment delay of >22 days (50% versus 38%,
P = 0.02); see also Figure 2.
Patients experiencing vertigo were more like to improve
than patients who did not (65% versus 35%; P = 0.03).
No other patient characteristics were signiﬁcantly associated
with improvement. After adjusting for vertigo, patients who
had testing more than 5 weeks after the ﬁrst dose of ITS
were6.7timesmorelikelytoshowimprovmentthanpatients
who had earlier testing (95% CI: 1.3, 35; P = 0.02) and
patients with vertigo were 6.2 times more likely to improve
than patients who did not experience vertigo (95% CI: 1.3,
29; P = 0.02), as shown in Table 5. Patients with vertigo
(12/40)startedtreatmentanaverageof18daysaftertheonset
of hearing loss while patients who did not experience vertigo
withtheirhearinglossstartedtreatmentanaverageof32days
after the onset of hearing loss (P = 0.07, paired t-test).
3.4. Complications. One patient experienced tinnitus for
several weeks after the ﬁrst injection which resolved spon-
taneously. All patients tolerated the procedure well. There
were no episodes of vertigo with the administration of the
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Figure 1: Scatterplot: time from deafness and time from intratym-
panic steroids (ITSs) to audiogram; hearing recovery in decibels
(dBs).



























Figure 2: Scatterplot: duration of deafness prior to ﬁrst dose of
intratympanic steroids (ITSs) and degree of hearing recovery in
decibels (dBs).
4. Discussion
Our data are similar to other reviews of ITS with regard to
demographics of ISSNHL and response rate to ITS; however,
our review diﬀers in that it speciﬁcally addresses the timing
of post-treatment audiograms when assessing treatment
response. Most other reviews report post-treatment audio-
grams as taking place during a certain range of weeks or
months after treatment has concluded, with all patients
falling within that stated range.4 International Journal of Otolaryngology
Table 4: Patient variables and associated response to treatment.
Overall (N = 40) Improvement (N = 18) No Improvement (N = 22)
N % N % N % P-value∗
Time to post-ITS audiogram
≤5 weeks 27 68 9 33 18 67 0.03
>5 weeks 13 33 9 69 4 31
Age, years
Mean (SD) 54 (18) 50 (18) 58 (18) 0.17
Gender
Male 20 50 8 40 12 60 0.53
Female 20 50 10 50 10 50
Ear
Left 26 65 10 38 16 62 0.26
Right 14 35 8 57 6 43
Days from onset to ITS
≤21 24 60 12 50 12 50 0.02
>21 16 40 6 38 10 63
Prior oral steroids
Yes 25 63 9 50 9 50 0.14
No 15 38 9 36 16 64
Vertigo
Yes 17 43 11 65 6 35 0.03
No 23 58 7 30 16 70
Tinnitus
Yes 27 68 14 52 13 48 0.21
No 13 33 4 31 9 69
∗P-values were computed using t-test for continuous characteristics and chi-square tests for categorical. ITS: intratympanic steroids; N: frequency; SD:
standard deviation.
Table 5: Adjusted odds of improvement (N = 40).
OR 95% CI P-value
Weeks to post-ITS audiogram >5w e e k sv e r s u s≤ 5 6.7 (1.3, 35) 0.02
Vertigo Yes versus No 6.2 (1.3, 29) 0.02
OR: odds ratio; CI: conﬁdence interval; ITS: intratympanic steroids.
Af e ws t u d i e sh a v er e p o r t e dt h eu s eo fs e r i a la u d i o g r a m s
during or immediately after the completion of treatment
with ITS. These studies have found that the greatest treat-
ment response is after the ﬁrst injection. Guan-Min et al.
[5] performed serial audiograms in patients who received
intratympanic dexamethaxone after failure with oral ster-
oids. Audiograms were performed after each of 3 injections.
The greatest response to treatment was 7 days after the ﬁrst
injection with a steadily decreasing steroid eﬀect thereafter.
There were signiﬁcant diﬀerences between the PTA after the
ﬁrst and third injection, corresponding to 7 and 21 days
after treatment began. Choung et al. [13] also performed
serial audiograms after intratympanic dexamethasone was
administered twice a week for 2 weeks. Audiograms were
performed after each injection and found a similar response
early,withthegreatestresponsein35.8%ofearsaftertheﬁrst
injection, 14.7% after the second, and 11.8% after the third;
however, Choung also performed an audiogram 1 week after
the ﬁnal injection. There was an increased response rate
from 11.8% on day 14 to 20.6% on day 21. Whether or
not this increased response represents a signiﬁcant delayed
response to treatment is uncertain. The studies of Guan-
MinandChoungprovidevaluableinformationregardingthe
early response to treatment with ITS but do not address the
response to treatment that may occur several weeks after the
completion of treatment.
Additional studies have been published which note a
more delayed response. Slattery et al. [14] reviewed their ex-
perience with oral steroids where audiograms were per-
formed on average 44 days after hearing loss. A subset of
those patients had an additional audiogram 4 months
(average) after the onset of hearing loss for comparison. A
statistically signiﬁcant improvement in the PTA was found
between the 44-day audiogram to the second post-treat-
ment audiogram. Battaglia et al. [12]p e r f o r m e dad o u b l e -
blinded, placebo-controlled, randomized study with patients
receiving either intratympanic dexamethasone and an oral
placebo, high-dose oral steroids and intratympanic saline, orInternational Journal of Otolaryngology 5
intratympanic dexamethasone and high-dose oral steroids.
Treatment was administered once a week for 3 weeks with
serial audiograms and an additional audiogram performed 4
weeks after the initial injection. Although not discussed in
their paper, the data suggest an increased probability of
improvement in all 3 groups when comparing the audio-
grams from immediately after treatment with those per-
formed at least 4 weeks after the initial injection. A statistical
analysis was not performed on this particular aspect of the
data.
By deﬁnition, ISSNHL is from an unknown etiology and
is a result of multiple unknown causes. Within this heter-
ogeneous group, there are likely to be early, late, and nonre-
sponders to steroid treatment. There may also be a number
of patients who are recovering spontaneously, regardless of
steroid therapy. This has been reported to be somewhere
between31%and65%[2,3,15,16].Nevertheless,thetiming
of the audiogram will determine the observed response;
therefore, when reporting results of idiopathic hearing loss,
studies should, at the least, report when the audiograms
were performed. Ideally, a series of audiograms should be
administered during and after treatment to document the
timing of treatment response. This will identify early versus
late responders and may provide important clues to the eti-
ology of hearing loss. It may also have implications with
regard to the determination of the length of treatment.
Another possibility to explain the late eﬀect of ITS is
how long it may aﬀect inner ear cells. Intratympanic meth-
ylprednisolone has been detected in the perilymph and en-
dolymph in guinea pigs for a fairly short duration; it achieves
its highest concentration at 1-2 hours and is present for
at least 6 hours, but it is no longer detectable at 24 hours
[17]. Despite the brief existence of steroids within the inner
ear ﬂuid, the eﬀect may be more durable and has not yet
been determined. Steroids eﬀect gene expression in cochlear
cells to alter both inﬂammatory processes [18] and ion ho-
meostasis [19, 20]. A delayed eﬀect of treatment may well
be via a mechanism that takes greater than 3 weeks to dem-
onstrate a measurable response.
Vertigo is often cited as a poor prognostic indicator for
sudden hearing loss mostly due to large reviews performed
prior to ITS in the 1970s and 1980s [15, 21, 22]. Most recent
studies involving ITS have reported that vertigo is not a
signiﬁcant prognostic indicator [5–7, 13, 23] while reports
of vertigo as a negative prognostic indicator are the minority
[24]. We found a signiﬁcantly higher rate of response to
ITS in patients who presented with vertigo. It has been
our experience that when patients experience vertigo with
their sudden hearing loss, they are much more likely to seek
prompt medical evaluation and are more likely to be referred
to a tertiary referral center. We believe that it is the shorter
interval between hearing loss and the start of treatment in
patients with vertigo (18 days to treatment) versus those who
did not (32 days to treatment) that best explains this result in
our series.
Like other reviews, our data are limited by not having
serial audiograms, which would better deﬁne when our pa-
tients responded to treatment. It is possible that the patients
in our group who had audiograms >5 weeks after the ﬁrst
dose of ITS responded sooner, which would have been
detected if their audiograms had been performed earlier.
However, our data diﬀer from the currently reported data in
that they show recovery occurring late, rather than early. In




Our observed response of a signiﬁcant number of patients
showingimprovementwhenaudiogramswereperformed>5
weeks after the ﬁrst dose of ITS is contrary to the idea that
response to treatment occurs early after starting treatment.
This may reﬂect a group of patients with delayed response
to steroid treatment. To better deﬁne when to perform post
treatment audiograms and to attempt to stratify patients
with ISSNHL as early or late responders, studies should
reportwhenaudiogramsareadministeredandshouldideally
have multiple audiograms to monitor response.
Disclosure
No ﬁnancial support was provided for this study. No author
has any ﬁnancial interest in the companies or products re-
ported in this paper or has any ﬁnancial disclosures related
to this work.
References
[1] S. D. Rauch, “Idiopathic sudden sensorineural hearing loss,”
New England Journal of Medicine, vol. 359, no. 8, pp. 788–840,
2008.
[2] W. R. Wilson, F. M. Byl, and N. Laird, “The eﬃcacy of steroids
in the treatment of idiopathic sudden hearing loss. A double-
blind clinical study,” Archives of Otolaryngology, vol. 106, no.
12, pp. 772–776, 1980.
[3] C. Y. Chen, C. Halpin, and S. D. Rauch, “Oral steroid treat-
ment of Sudden Sensorineural Hearing Loss: a ten year ret-
rospective analysis,” Otology and Neurotology, vol. 24, no. 5,
pp. 728–733, 2003.
[4] A. E. Conlin and L. S. Parnes, “Treatment of sudden sen-
sorineural hearing loss II. A meta-analysis,” Archives of Ot-
olaryngology, vol. 133, no. 6, pp. 582–586, 2007.
[5] H. Guan-Min, L. Hung-Ching, S. Min-Tsan, Y. Cheng-Chien,
a n dT .H s u n - T i e n ,“ E ﬀectiveness of intratympanic dexam-
ethasone injection in sudden-deafness patients as salvage
treatment,”Laryngoscope,vol.114,no.7,pp.1184–1189,2004.
[6] D. S. Haynes, M. O’Malley, S. Cohen, K. Watford, and R.
F. Labadie, “Intratympanic dexamethasone for sudden sen-
sorineural hearing loss after failure of systemic therapy,” Lar-
yngoscope, vol. 117, no. 1, pp. 3–15, 2007.
[7] G.PlazaandC.Herr´ aiz,“Intratympanicsteroidsfortreatment
of sudden hearing loss after failure of intravenous therapy,”
Otolaryngology, vol. 137, no. 1, pp. 74–78, 2007.
[8] D. C. Fitzgerald and J. F. McGuire, “Intratympanic steroids
for idiopathic sudden sensorineural hearing loss,” Annals of
Otology, Rhinology and Laryngology, vol. 116, no. 4, pp. 253–
256, 2007.
[9] W. H. Slattery, L. M. Fisher, Z. Iqbal, R. A. Friedman, and
N. Liu, “Intratympanic steroid injection for treatment of6 International Journal of Otolaryngology
idiopathic sudden hearing loss,” Otolaryngology, vol. 133, no.
2, pp. 251–259, 2005.
[10] S. S. Chandrasekhar, “Intratympanic dexamethasone for sud-
den sensorineural hearing loss: clinical and laboratory evalua-
tion,” Otology and Neurotology, vol. 22, no. 1, pp. 18–23, 2001.
[11] G. J. Gianoli and J. C. Li, “Transtympanic steroids for treat-
ment of sudden hearing loss,” Otolaryngology, vol. 125, no. 3,
pp. 142–146, 2001.
[12] A. Battaglia, R. Burchette, and R. Cueva, “Combination ther-
apy (intratympanic dexamethasone + high-dose prednisone
taper) for the treatment of idiopathic sudden sensorineural
hearing loss,” Otology and Neurotology, vol. 29, no. 4, pp. 453–
460, 2008.
[13] Y. H. Choung, K. Park, Y. R. Shin, and M. J. Cho, “Intratym-
panic dexamethasone injection for refractory sudden sensor-
ineural hearing loss,” Laryngoscope, vol. 116, no. 5, pp. 747–
752, 2006.
[14] W. H. Slattery, L. M. Fisher, Z. Iqbal, and N. Liu, “Oral steroid
regimens for idiopathic sudden sensorineural hearing loss,”
Otolaryngology, vol. 132, no. 1, pp. 5–10, 2005.
[15] D. E. Mattox and F. B. Simmons, “Natural history of sudden
sensorineural hearing loss,” Annals of Otology, Rhinology and
Laryngology, vol. 86, no. 4, pp. 463–480, 1977.
[16] U. Cinamon, E. Bendet, and J. Kronenberg, “Steroids, carbo-
gen or placebo for sudden hearing loss: a prospective double-
blind study,” European Archives of Oto-Rhino-Laryngology, vol.
258, no. 9, pp. 477–480, 2001.
[17] L. S. Parnes, A. H. Sun, and D. J. Freeman, “Corticosteroid
pharmacokinetics in the inner ear ﬂuids: an animal study
followed by clinical application,” Laryngoscope, vol. 109, no.
7, pp. 1–17, 1999.
[18] M. Hamid and D. Trune, “Issues, indications, and controver-
siesregardingintratympanicsteroidperfusion,”Current Opin-
ion in Otolaryngology and Head and Neck Surgery, vol. 16, no.
5, pp. 434–440, 2008.
[19] T. Kitahara, M. Fukushima, Y. Uno, Y. Mishiro, and T. Kubo,
“Up-regulation of cochlear aquaporin-3 mRNA expression
after intra-endolymphatic sac application of dexamethasone,”
Neurological Research, vol. 25, no. 8, pp. 865–870, 2003.
[ 2 0 ]D .R .T r u n e ,J .B .K e m p t o n ,A .R .H a r r i s o n ,a n dJ .L .
Wobig, “Glucocorticoid impact on cochlear function and
systemic side eﬀects in autoimmune C3.MRL-Faslpr and
normal C3H/HeJ mice,” Hearing Research, vol. 226, no. 1-2,
pp. 209–217, 2007.
[21] F. M. Byl, “Sudden hearing loss: eight years’ experience and
suggested prognostic table,” Laryngoscope,v o l .9 4 ,n o .5 ,p p .
647–661, 1984.
[22] F. T. Shaia and J. L. Sheehy, “Sudden sensori-neural hearing
impairment:areportof1,220cases,”Laryngoscope,vol.86,no.
3, pp. 389–398, 1976.
[23] I. Dallan, A. De Vito, B. Fattori et al., “Intratympanic meth-
ylprednisolone in refractory sudden hearing loss: a 27-patient
case series with univariate and multivariate analysis,” Otology
and Neurotology, vol. 31, no. 1, pp. 25–30, 2010.
[24] J. Xenellis, N. Papadimitriou, T. Nikolopoulos et al., “Intrat-
ympanic steroid treatment in idiopathic sudden sensorineural
hearing loss: a control study,” Otolaryngology, vol. 134, no. 6,
pp. 940–945, 2006.